Advertisement

Cognitive Therapy and Research

, Volume 43, Issue 5, pp 937–947 | Cite as

d-Cycloserine-Augmented Behavior Therapy for Body Dysmorphic Disorder: A Preliminary Efficacy Trial

  • Hilary WeingardenEmail author
  • Suraj S. Mothi
  • Ilana Ladis
  • Susanne Hoeppner
  • Hannah E. Reese
  • Kiara Timpano
  • Jedidiah Siev
  • Jessica Rasmussen
  • Jennifer Ragan
  • Darin D. Dougherty
  • Sabine Wilhelm
Original Article

Abstract

Cognitive behavioral therapy (CBT) is the leading psychotherapeutic treatment for body dysmorphic disorder (BDD), yet not all patients improve. To address the treatment response gap, CBT may be augmented with cognitive enhancers such as d-cycloserine (DCS). DCS-augmented behavior therapy has been tested with mixed results in related disorders. To initially test whether DCS may augment CBT for BDD, we conducted the first preliminary efficacy trial of DCS versus placebo-augmented CBT for BDD, via a randomized, double-blind study. We analyzed data using mixed-effects models in a modified intent-to-treat sample (N = 26). Over 10 weeks of treatment, primary (BDD severity) and secondary (insight, depression) outcomes improved significantly across both conditions, but there were no significant group differences in response. Exploratory analysis revealed that BDD-related distress, specifically, reduced significantly more in the DCS condition compared to placebo. This is the first study testing DCS-augmented CBT for BDD. Implications, limitations, and future directions are discussed.

Trial registry: ClinicalTrials.gov Identifier NCT00842309

Keywords

Body dysmorphic disorder Behavior therapy d-Cycloserine Cognitive enhancers 

Notes

Acknowledgements

We would like to thank the reviewers, whose comments on an earlier version of this manuscript contributed to substantial improvements in the paper.

Funding

This work was supported by the Neil and Anna Rasmussen Foundation and the David Judah Fund. The funding sources played no role in design of this study; the collection, analysis, and interpretation of data; the writing of this report; or the decision to submit this article for publication.

Compliance with Ethical Standards

Conflict of interest

Drs. Weingarden and Wilhelm and Ms. Ladis have received salary support from Telefonica Alpha, Inc. Dr. Wilhelm has received research support in the form of free medication and matching placebo from Forest Laboratories for clinical trials funded by the NIH. Dr. Wilhelm is a presenter for the Massachusetts General Hospital Psychiatry Academy in educational programs supported through independent medical education grants from pharmaceutical companies; she has received royalties from Elsevier Publications, Guilford Publications, New Harbinger Publications, and Oxford University Press. Dr. Wilhelm has also received speaking honorarium from various academic institutions and foundations, including the International Obsessive Compulsive Disorder Foundation and the Tourette Association of America. In addition, she received payment from the Association for Behavioral and Cognitive Therapies for her role as Associate Editor for the Behavior Therapy journal, as well as from John Wiley & Sons, Inc. for her role as Associate Editor on the journal Depression & Anxiety. Dr. Wilhelm has also received salary support from Novartis. Dr. Dougherty has received research support from Medtronic and LivaNova. Suraj S. Mothi, Susanne Hoeppner, Hannah E. Reese, Kiara Timpano, Jedidiah Siev, Jessica Rasmussen and Jennifer Ragan declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Animal Rights

No animal studies were carried out by the authors for this article.

References

  1. American Psychiatric Association [APA]. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Association.CrossRefGoogle Scholar
  2. Andersson, E., Hedman, E., Enander, J., Djurfeldt, D. R., Ljótsson, B., Cervenka, S., Isung, J., Svanborg, C., Mataix-Cols, D., Kaldo, V., Andersson, G., Lindefors, N., & Rück, C. (2015). d-Cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: A randomized clinical trial. JAMA Psychiatry, 72, 659–667.  https://doi.org/10.1001/jamapsychiatry.2015.0546.CrossRefPubMedGoogle Scholar
  3. Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck depression inventory-second edition: manual. San Antonio, TX: Psychological Corporation.Google Scholar
  4. Buhlmann, U., Glaesmer, H., Mewes, R., Fama, J. M., Wilhelm, S., Brähler, E., & Rief, W. (2010). Updates on the prevalence of body dysmorphic disorder: A population-based survey. Psychiatry Research, 178, 171–175.  https://doi.org/10.1016/j.psychres.2009.05.002.CrossRefPubMedGoogle Scholar
  5. Chasson, G. S., Buhlmann, U., Tolin, D. F., Rao, S. R., Reese, H. E., Rowley, T., Welsh, K., & Wilhelm, S. (2010). Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behaviour Research and Therapy, 48, 675–679.  https://doi.org/10.1016/j.brat.2010.03.007.CrossRefPubMedGoogle Scholar
  6. Davis, M., & Myers, K. M. (2002). The role of glutamate and gamma-aminobutyric acid in fear extinction: Clinical implications for exposure therapy. Biological Psychiatry, 52, 998–1007.CrossRefPubMedGoogle Scholar
  7. de Leeuw, A. S., van Megen, H. J. G. M., Kahn, R. S., & Westenberg, H. G. M. (2017). d-Cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder. European Psychiatry, 40, 38–44.  https://doi.org/10.1016/j.eurpsy.2016.06.011.CrossRefPubMedGoogle Scholar
  8. Eisen, J. L., Phillips, K. A., Baer, L., Beer, D. A., Atala, K. D., & Rasmussen, S. A. (1998). The Brown Assessment of Beliefs Scale: Reliability and validity. American Journal of Psychiatry. 155. 102–108.  https://doi.org/10.1176/ajp.155.1.102..CrossRefPubMedGoogle Scholar
  9. Fang, A., & Hofmann, S. G. (2010). Relationship between social anxiety disorder and body dysmorphic disorder. Clinical Psychology Review, 30, 1040–1048.  https://doi.org/10.1016/j.cpr.2010.08.001.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Farrell, L. J., Waters, A. M., Boschen, M. J., Hattingh, L., McConnell, H., Milliner, E. L., Collings, N., Zimmer-Gembeck, M., Shelton, D., Ollendick, T. H., Testa, C., & Storch, E. A. (2013). Difficult-to-treat pediatric obsessive-compulsive disorder: Feasibility and preliminary results of a randomized pilot trial of d-cycloserine-augmented behavior therapy. Depression and Anxiety, 30, 723–731.  https://doi.org/10.1002/da.22132.CrossRefPubMedGoogle Scholar
  11. First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. (2002). The structured clinical interview for the DSM-IV-TR Axis I disorders (SCID-I/P). (Research version, patient ed.). New York: Biometrics Research.Google Scholar
  12. Guastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R. (2008). A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry, 63, 544–549.  https://doi.org/10.1016/j.biopsych.2007.11.011.CrossRefPubMedGoogle Scholar
  13. Gueorguieva, R., & Krystal, J. H. (2004). Move over ANOVA: Progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Archives of General Psychiatry, 61, 310–317.  https://doi.org/10.1001/archpsyc.61.3.310.CrossRefPubMedGoogle Scholar
  14. Hedges, L., & Olkin, I. (1985). Statistical methods for meta-analysis. New York: Academic Press.Google Scholar
  15. Hedges, L. V. (1981). Distribution theory for Glass’s estimator of effect size and related estimators. Journal of Educational and Behavioral Statistics, 6, 107–128.  https://doi.org/10.3102/10769986006002107.CrossRefGoogle Scholar
  16. Hofmann, S. G. (2016). Schrödinger’s cat and d-cycloserine to augment exposure therapy-both are alive and dead. JAMA Psychiatry, 73, 771–772.  https://doi.org/10.1001/jamapsychiatry.2016.1132.CrossRefPubMedGoogle Scholar
  17. Hofmann, S. G., Carpenter, J. K., Otto, M. W., Rosenfield, D., Smits, J. A. J., & Pollack, M. H. (2015). Dose timing of d-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemporary Clinical Trials, 43, 223–230.  https://doi.org/10.1016/j.cct.2015.06.015.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Hofmann, S. G., Meuret, A. E., Smits, J. A., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006). Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Archives of General Psychiatry, 63, 298.  https://doi.org/10.1001/archpsyc.63.3.298.CrossRefPubMedGoogle Scholar
  19. Hofmann, S. G., Otto, M. W., Pollack, M. H., & Smits, J. A. (2015). d-Cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: An update. Current Psychiatry Reports, 17, 532.  https://doi.org/10.1007/s11920-014-0532-2.CrossRefPubMedGoogle Scholar
  20. Hofmann, S. G., Smits, J. A., Rosenfield, D., Simon, N. M., Otto, M. W., Meuret, A. E., Fang, A., Tart, C., & Pollack, M. H. (2013). d-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. America Journal of Psychiatry, 170, 751–758.  https://doi.org/10.1176/appi.ajp.2013.12070974.CrossRefGoogle Scholar
  21. Koran, L. M., Abujaoude, E., Large, M. D., & Serpe, R. T. (2008). The prevalence of body dysmorphic disorder in the United States adult population. CNS Spectrums, 13, 316–322.CrossRefPubMedGoogle Scholar
  22. Kushner, M. G., Kim, S. W., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., McCabe, J., Peterson, J., & Foa, E. B. (2007). D-Cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry, 62, 835–838.  https://doi.org/10.1016/j.biopsych.2006.12.020.CrossRefPubMedGoogle Scholar
  23. Mataix-Cols, D., Fernández de la Cruz, L., Monzani, B., Rosenfield, D., Andersson, E., Pérez-Vigil, A., & Rück, C. (2017). D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: A systematic review and meta-analysis of individual participant data. JAMA Psychiatry, 74, 501–510.  https://doi.org/10.1001/jamapsychiatry.2016.3955.CrossRefPubMedGoogle Scholar
  24. Mataix-Cols, D., Turner, C., Monzani, B., Isomura, K., Murphy, C., Krebs, G., & Heyman, I. (2014). Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: Pilot randomised controlled trial. British Journal of Psychiatry, 204, 77–78.  https://doi.org/10.1192/bjp.bp.113.126284.CrossRefPubMedGoogle Scholar
  25. Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A., van Minnen, A., Evins, A. E., & Pollack, M. H. (2016). Enhancement of psychosocial treatment with d-cycloserine: Models, moderators, and future directions. Biological Psychiatry, 80, 274–283.  https://doi.org/10.1016/j.biopsych.2015.09.007.CrossRefPubMedGoogle Scholar
  26. Phillips, K. A., Hart, A. S., & Menard, W. (2014). Psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS). Journal of Obsessive Compulsive and Related Disorders, 3, 205–208.CrossRefGoogle Scholar
  27. Phillips, K. A., Hart, A. S., Menard, W., & Eisen, J. L. (2013). Psychometric evaluation of the Brown Assessment of Beliefs Scale in body dysmorphic disorder. Journal of Nervous and Mental Disease, 201, 640–643.  https://doi.org/10.1097/NMD.0b013e3182983041.CrossRefPubMedGoogle Scholar
  28. Phillips, K. A., Hollander, E., Rasmussen, S. A., & Aronowitz, B. R. (1997). A severity rating scale for body dysmorphic disorder: Development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacology Bulletin, 33, 17–22.PubMedGoogle Scholar
  29. Rief, W., Buhlmann, U., Wilhelm, S., Borkenhagen, A., & Brahler, E. (2006). The prevalence of body dysmorphic disorder: A population-based survey. Psychological Medicine, 36, 877–885.  https://doi.org/10.1017/S0033291706007264.CrossRefPubMedGoogle Scholar
  30. SAS Institute, Inc. (2016). The SAS system for Windows, version 9.4. Cary, NC: SAS Institute, Inc.Google Scholar
  31. Schieber, K., Kollei, I., de Zwaan, M., & Martin, A. (2015). Classification of body dysmorphic disorder—What is the advantage of the new DSM-5 criteria? Journal of Psychosomatic Research, 78, 223–227.  https://doi.org/10.1016/j.jpsychores.2015.01.002.CrossRefPubMedGoogle Scholar
  32. Smits, J. A. J., Rosenfield, D., Otto, M. W., Marques, L., Davis, M. L., Meuret, A. E., Simon, N. M., Pollack, M. H., & Hofmann, S. G. (2013). d-Cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. Journal of Psychiatric Research, 47, 1455–1461.  https://doi.org/10.1016/j.jpsychires.2013.06.020.CrossRefPubMedPubMedCentralGoogle Scholar
  33. Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirch, A., Fernandez, M., Geffken, G. R., & Goodman, W. K. (2007). D-Cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology, 22, 230–237.  https://doi.org/10.1097/YIC.0b013e32819f8480.CrossRefPubMedGoogle Scholar
  34. Storch, E. A., Murphy, T. K., Goodman, W. K., Geffken, G. R., Lewin, A. B., Henin, A., Micco, J. A., Sprich, S., Wilhelm, S., Bengston, M., & Geller, D. A. (2010). A preliminary study of D-cycloserine augmentation of cognitive-nehavioral therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry, 68, 1073–1076.  https://doi.org/10.1016/j.biopsych.2010.07.015.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Storch, E. A., Wilhelm, S., Sprich, S., Henin, A., Micco, J., Small, B. J., McGuire, J., Mutch, P. J., Lewin, A. B., Murphy, T. K., & Geller, D. A. (2016). Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-cycloserine vs placebo in pediatric obsessive-compulsive disorder: A randomized clinical trial. JAMA Psychiatry, 73, 779–788.  https://doi.org/10.1001/jamapsychiatry.2016.1128.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Veale, D., Anson, M., Miles, S., Pieta, M., Costa, A., & Ellison, N. (2014). Efficacy of cognitive behaviour therapy versus anxiety management for body dysmorphic disorder: A randomised controlled trial. Psychotherapy and Psychosomatics, 83, 341–353.  https://doi.org/10.1159/000360740.CrossRefPubMedGoogle Scholar
  37. Veale, D., & Neziroglu, F. (2010). Body dysmorphic disorder: A treatment manual. West Sussex: Wiley-Blackwell.CrossRefGoogle Scholar
  38. Walker, D. L., Ressler, K. J., Lu, K. T., & Davis, M. (2002). Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. The Journal of Neuroscience, 22, 2343–2351.CrossRefPubMedGoogle Scholar
  39. Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L. (2008). Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry, 165, 335–341.  https://doi.org/10.1176/appi.ajp.2007.07050776. (quiz 409).CrossRefPubMedGoogle Scholar
  40. Wilhelm, S., Phillips, K. A., Didie, E., Buhlmann, U., Greenberg, J. L., Fama, J. M., Keshaviah, A., & Steketee, G. (2014). Modular cognitive-behavioral therapy for body dysmorphic disorder: A randomized controlled trial. Behavior Therapy, 45, 314–327.  https://doi.org/10.1016/j.beth.2013.12.007.CrossRefPubMedGoogle Scholar
  41. Wilhelm, S., Phillips, K. A., & Steketee, G. (2013). Cognitive-behavioral therapy for body dysmorphic disorder: A treatment manual. New York: Guilford Press.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Hilary Weingarden
    • 1
    Email author
  • Suraj S. Mothi
    • 2
  • Ilana Ladis
    • 1
  • Susanne Hoeppner
    • 1
  • Hannah E. Reese
    • 3
  • Kiara Timpano
    • 4
  • Jedidiah Siev
    • 5
  • Jessica Rasmussen
    • 1
  • Jennifer Ragan
    • 1
  • Darin D. Dougherty
    • 1
    • 6
  • Sabine Wilhelm
    • 1
  1. 1.Department of PsychiatryMassachusetts General Hospital & Harvard Medical SchoolBostonUSA
  2. 2.Department of MedicineRenal Division, Brigham and Women’s HospitalBostonUSA
  3. 3.Department of PsychologyBowdoin CollegeBrunswickUSA
  4. 4.Department of PsychologyUniversity of MiamiCoral GablesUSA
  5. 5.Department of PsychologySwarthmore CollegeSwarthmoreUSA
  6. 6.Mclean Hospital & Harvard Medical SchoolBelmontUSA

Personalised recommendations